Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q2

4574.TEDINET S100RMXK
Period2023-01-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥2.5bn2023-01-01 → 2023-06-30Cons.Net sales
Revenue¥5.0bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥1.9bn2022-01-01 → 2022-06-30Cons.Net sales
Operating income−¥396m2023-01-01 → 2023-06-30Cons.Operating income
Operating income−¥2.4bn2022-01-01 → 2022-06-30Cons.Operating income
Ordinary income−¥510m2023-01-01 → 2023-06-30Cons.Ordinary income
Ordinary income−¥3.4bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.5bn2022-01-01 → 2022-06-30Cons.Ordinary income
Profit before tax−¥492m2023-01-01 → 2023-06-30Cons.Income before income taxes
Profit before tax−¥2.8bn2022-01-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)−¥514m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.8bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income−¥514m2023-01-01 → 2023-06-30Cons.Profit loss
Net income−¥2.8bn2022-01-01 → 2022-06-30Cons.Profit loss
Total assets¥15.6bnat 2023-06-30Cons.Assets
Total assets¥15.0bnat 2022-12-31Cons.Assets
Total assets¥17.4bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥6.5bnat 2023-06-30Cons.Liabilities
Total liabilities¥7.0bnat 2022-12-31Cons.Liabilities
Net assets / equity¥9.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥8.0bnat 2022-12-31Cons.Net assets
Net assets / equity¥10.2bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥4.8bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥3.1bnat 2022-12-31Cons.Cash and deposits
Cash & equivalents¥4.5bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.8bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.4bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.5bnat 2021-12-31dCons.Cash and cash equivalents
Operating cash flow¥126m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥2.0bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥631m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities
Investing cash flow¥707m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Investing cash flow¥190m2022-01-01 → 2022-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥96m2022-01-01 → 2022-06-30Cons.Net cash provided by used in investment activities
Financing cash flow¥827m2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥997m2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥501m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-11.362023-01-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.762023-04-01 → 2023-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-112.262022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-64.172022-01-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-24.052022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio58.7%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio53.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.4%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Otherother segmentsrevenue2023-01-01 → 2023-06-30¥2m
Otherother segmentsrevenue external2023-01-01 → 2023-06-30¥2m
Otherother segmentssegment profit2023-01-01 → 2023-06-30−¥11m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥492m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥370m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥370m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥407m
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥514m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-06-30¥2.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-06-30¥2.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-06-30¥95m
Otherother segmentsrevenue2022-01-01 → 2022-06-30¥4m
Otherother segmentsrevenue external2022-01-01 → 2022-06-30¥4m
Otherother segmentssegment profit2022-01-01 → 2022-06-30−¥11m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-06-30−¥645m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥365m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥365m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.6bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.5bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.5bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥117m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-06-30−¥1.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 510
ItemContextValueUnit
Details of employee share option program (text)FilingDateInstantText · Plus
Other information on share acquisition rights (text)FilingDateInstantText · Plus
Exercises etc of moving strike convertible bonds etc (text)FilingDateInstantText · Plus
Changes in number of issued shares stated capital etc (text)FilingDateInstantText · Plus
Major shareholders (text)FilingDateInstantText · Plus
Name major shareholdersCurrentQuarterInstant_No1MajorShareholdersMemberText · Plus
Address major shareholdersCurrentQuarterInstant_No1MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)柴田　高
Address major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)大阪府吹田市
Name major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)柴田　仁
Address major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)大阪府吹田市
Name major shareholdersCurrentQuarterInstant_No4MajorShareholdersMember
Original text (Japanese)日本マスタートラスト信託銀行株式会社（信託口）
Address major shareholdersCurrentQuarterInstant_No4MajorShareholdersMember
Original text (Japanese)東京都港区浜松町２丁目11番３号
Name major shareholdersCurrentQuarterInstant_No5MajorShareholdersMember
Original text (Japanese)UBS AG HONG KONG （常任代理人　シティバンク、エヌ・エイ東京支店）
Address major shareholdersCurrentQuarterInstant_No5MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No6MajorShareholdersMemberText · Plus
Address major shareholdersCurrentQuarterInstant_No6MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)柴田　晃宏
Address major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)大阪府吹田市
Name major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)アース製薬株式会社
Address major shareholdersCurrentQuarterInstant_No8MajorShareholdersMember
Original text (Japanese)東京都千代田区神田司町２丁目12－１
Name major shareholdersCurrentQuarterInstant_No9MajorShareholdersMember
Original text (Japanese)興和株式会社
Address major shareholdersCurrentQuarterInstant_No9MajorShareholdersMember
Original text (Japanese)愛知県名古屋市中区錦３丁目６番29号
Name major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)柴田　航
Address major shareholdersCurrentQuarterInstant_No10MajorShareholdersMember
Original text (Japanese)東京都港区
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesWithFullVotingRightsOtherMember－
Description issued shares voting rightsCurrentQuarterInstant_SharesLessThanOneUnitMember－
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)大幸薬品株式会社
Address of shareholder treasury shares etcCurrentQuarterInstant_Row1Member
Original text (Japanese)大阪府吹田市内本町三丁目34番14号
Information about officers (text)FilingDateInstantText · Plus
Regulations in accordance with which consolidated financial statements have been prepared financial informationCurrentYTDDurationText · Plus
Note on independent audit financial informationCurrentYTDDurationText · Plus
Quarterly consolidated balance sheet (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of income (text)CurrentYTDDurationText · Plus
Year to quarter end consolidated statement of comprehensive income (text)CurrentYTDDurationText · Plus
Quarterly consolidated statement of cash flows (text)CurrentYTDDurationText · Plus
Debtors notes regarding overdraft contracts and or loan commitments (text)CurrentQuarterInstantText · Plus
Notes regarding write downs of inventories (text)CurrentYTDDurationText · Plus
Major components of selling general and administrative expenses (text)CurrentYTDDurationText · Plus
Premium allowance of retirement (text)CurrentYTDDurationText · Plus
Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text)CurrentYTDDurationText · Plus
Notes regarding dividend (text)Prior1YTDDurationText · Plus
Notes regarding dividend (text)CurrentYTDDurationText · Plus
Notes when there is significant changes in amounts of equity (text)CurrentYTDDurationText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass